Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Allied Corp Files for Full Psilocybin Patent for Psilonex Rx Pharmaceutical
Details : The patent describes that the Psilonex RX, entourage effect of both the specific psilocybin treatment period followed by a cannabidiol (CBD) cannabis derivative compound.
Product Name : Psilonex RX
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine,Cordyceps,Lion\'s mane
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : HAVN Life Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex™ RX
Details : Allied has under provisional patent the formulation and trademark for Psilonex™ RX. Along with this, Allied has access to a cohort of over 300 veterans, police, fire and ambulance personnel who are struggling with post trauma symptoms and are requestin...
Product Name : Psilonex RX
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Psilocybine,Cordyceps,Lion\'s mane
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : HAVN Life Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ALID-10
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Allied Corp. Strengthens IP and Pharma Strategy by Filing Provisional Patent for ALID-10 and ALID-11
Details : The patent application covers Allied’s proprietary products, ALID-10 and ALID-11, as well as other novel cannabis derived compounds designed for superior pharmaceutical properties for treatment of PTSD and other mental disorders.
Product Name : ALID-10
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : ALID-10
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable